ATB-330

ATB-330
Product Description

[ALK5 inhibitor / Small Molecule / Develop for IPF and Fibrosis) – Complete to derivate the lead compound

1. Confirm the highest ALK5 selectivity with superior efficacy and PK profile through in-vivo tests compared to competitors (small molecule new drugs) 

2. For IPF treatment, develop as inhalation therapy to avoid systemic exposure and minimize possible toxicities
-  ALK5 inhibitor projects are dropped due to the side effects such as hepatotoxicity, skin toxicity, and cardiotoxicity through systemic circulation in clinical trials

3. Confirm the superior efficacy compared to the standard therapy of IPF through in-vivo tests 

Read more Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
View company profile
Categories
more categories Show less

Autotelic Bio

  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2021
  • Employees:
    25 - 49
Company types
Manufacturer/Innovator
View company profile

More Products from Autotelic Bio (2)

  • ATB-101

    Product ATB-101

    [ARB+SGLT-2i Fixed Dose Combination] – In process of Phase 3 clinical trial on approx. 250 patients
    1. The first Fixed Dose Combination treating hypertension and type 2 diabetes by a tablet in the world

    2. Expect the synergistic effect in the treatment of hypertension though mi...
  • ATB-301

    Product ATB-301

    [TGF-β2 Targeting ASO (TASO) + IL-2 Combination therapy] - Phase Ib

    1. Confirm the potential of TGF-β2 as a biomarker in human blood and tumor tissues from the efficacy result of Phase Ib clinical trial on cancer patients 

    2. Confirm the suppression of IL-2’s side effect in combinati...

Autotelic Bio resources (1)